Advanced Therapies Integrates 2021 Agenda

Welcome and Opening Remarks

09:15-09:30

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Session 1:

09:35- 10:25

Let’s get clinical

• Evaluation and Development for ATMPs is different from the ‘norm’; do we need to rethinking the design of clinical trials for a clear path to commercialisation.
• Taking learnings from Covid-19 (vaccines), i.e., efficiency in a crisis – what can we learn?

Session 2:

10:35-11:25

Britain’s talent for technology

Does the UK have the right skills and capabilities in place to identify and develop the next generation of ATMPs?

NETWORKING

11:30-11:50

Session 3:

11:55-12:45

Precision Thinking

How to expand the development and use of Autologus ATMPs.

NETWORKING

13:50-14:20

Session 5:

14:25-15:15

Fast Forward

What are the emerging therapeutic technologies and what will the next generation of ATMPs look like?
Do we have the right capabilities and assets to manufacture them?

Closing Remarks

15:20-15:30

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Welcome and Opening Remarks

09:15-09:30

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Session 1:

09:35- 10:25

Finding the Funds

Are the existing approaches to financing ATMP developers fit for purpose; what should analysts really be looking for in an Advanced Therapy?

Session 2:

10:35-11:25

Advanced Relays

Evolving the relationship between developers, regulators, payers, providers and patients to speed ATMP development through to adoption. How healthy are the Technology Assessments for ATMPs, are they revealing the full value?

NETWORKING

11:30-11:50

Session 3:

11:55-12:45

Export Strength

What are the current challenges and future opportunities for opening up the ATMP markets?
MHRA, NICE and NHS England are working together can make the UK attractive, but there are lower number of patients in UK as opposed to Europe. So how attractive is the UK for investment? How can investors get quicker and better returns?
Divergence from MHRA and EMA

Session 4:

12:55-13:45

Go with the (cash) flow

Investments and infrastructure have been put in place to rapidly translate ATMPs from concept to clinic. But are we doing enough?

NETWORKING

13:50-14:20

Session 5:

14:25-15:15

Skills: the global gold rush

How can stakeholders come together to address cell and gene therapy’s global talent gap?

Closing Remarks

15:20-15:30

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Welcome and Opening Remarks

09:15-09:30

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult

Session 1:

09:35- 10:25

Making Waves: Technologies and development improvements

How good are we at making Advanced Therapies today, what should the future look like?
Focusing on manufacturing technologies and analytical methods and the role of High throughput and automation.

Session 2:

10:35-11:25

Supply Pain

As more ATMPs progress towards the market, there are significant emergent challenges to the supply chain.
What needs to happen to ensure therapies are effectively and efficiently produced?

NETWORKING

11:30-11:50

Session 3:

11:55-12:45

Productive People

As manufacturing technologies continues to emerge, we must have the skills to deliver the science at scale. How can we ensure that talent tracks with emergent manufacturing trends?

Session 4:

12:55-13:45

Due process: GMP translation and manufacture

Shortening upstream and downstream process is key to cost and natural resource savings and efficiencies for ATMPs. Can we share knowledge for the greater good of patients and the planet?

NETWORKING

13:50-14:20

Session 5:

14:25-15:15

Negotiate or collaborate?

In an ever-changing pharmaceutical landscape, successfully bringing a concept to market — and to patients — involves many different stakeholders. How do industry leaders navigate this journey most effectively?

Closing Remarks

15:20-15:30

SHARON BROWNLOW | Chief Business Officer | Cell & Gene Therapy Catapult